Cancer incidences increase in people living with HIV/AIDS. Over 2 million people currently live with HIV/AIDS in the US. This number will increase as HAART prolongs the average lifespan and as (at least in some states) the number of new HIV infections increase again. As this population ages their incidence rates for cancer will increase, as well. Recently, new rational targets for cancer therapy have emerged. But their application to the care of HIV+ patients is slow, because of concerns about the weakened immune status of the patients, because of possible drug interactions with HAART and because some of the AIDS defining cancer are rare.

Hersteller:
Springer Verlag GmbH
juergen.hartmann@springer.com
Tiergartenstr. 17
DE 69121 Heidelberg

Foreword -J. Pagano, UNC Linberger Comprehensive Cancer Center Epidemiology of AIDS defining Cancers - D. Whitby, NCI Frederick - J. Martin, UC San Francisco Interferon-alpha therapy for Kaposi sarcoma - Susan E. Krown, Memorial Sloan Kettering Cancer Center Rapamycin and mTOR inhibitors in primary effusion lymphoma and Kaposi sarcoma - B. Damania, UNC Linberger Comprehensive Cancer Center - S. Montaner, U. Maryland Gleevec/cKIT inhibitors in Kaposi sarcoma - Henry Koon, Cleveland Clinic - Ashely Moses, Oregon Health Sciences Center Combating EBV lymphoma by induction of the lytic phase - S. Kenney, U. Wisconsin, Madison Gene therapy of lymphoma and Kaposi sarcoma - C. Boshoff, University College London Nutlin--Targeting p53 in Primary effusion lymphoma P. Ojala, U. Helsinki Metronomic therapy for Kaposi sarcoma - R. Rocheford, SUNY Upstate Inflammatory cytokine dysregulation in AIDS- associated cancers - F. Neipel, U. Erlangen - O. Martinez-Maza, UCLA - J. Nicholas, Johns Hopkins University Cidofovir against Human Papilloma virus -associated cancers J. Palefsky, UC San Francisco; E. Stier, Boston Medical Center Targeting EGFR (Cetuximab) in Human Papilloma virus associated anal cancer Joe Sparano Montefiore Hospital, Bronx, NY Vaccination against human papilloma virus in HIV+ individuals - J. Schiller, NCI Bethesda - D. Lowry, NCI Bethesda Treating Hodgkin lymphoma in the HIV+ patient - R. Ambinder, John Hopkins U. Immune reconstitution syndrome associated cancers - Corey Casper, Fred Hutchinson Cancer Center, U. Washington. - J. Vierra, Fred Hutchinson Cancer Center, U. Washington. Treating AIDS-defining malignances in resource constrained settings - W. Harrington, U. Miami Sylvester Cancer Center - C. vanDerHorst, UNC Chapel Hill Center for AIDS research NFkappaB inhibitors in AIDS-defining Cancers - A. Baldwin, UNC Lineberger Comprehensive Cancer Center - D. Dittmer, UNC Lineberger Comprehensive Cancer Center Clinical trials in the HIV+ population - R. Mitsuyasu, UCLA - R. Little, NCI Bethesda Epidemiology of common non-AIDS-defining cancers in the HIV+ population - E. Engles, NCI Viral Epidemiology branch, Bethesda - J. Lee, U. Alabama Birmingham Clinical manifestations of common cancers in the HIV+ - R. Yarchoan, NCI Bethesda - B. Dezube, Harvard University School of Medicine